-+ 0.00%
-+ 0.00%
-+ 0.00%
Future Science & Technology Holdings joins KRW 7 billion Series A for RNA therapy developer
Share
Listen to the news
Future Science & Technology Holdings joins KRW 7 billion Series A for RNA therapy developer
  • Future Science & Technology Holdings participated in anti-aging RNA developer Lifelex Science's KRW 7 billion Series A financing announced on the 13th.
  • Proceeds will fund clinical trial preparations and trials for its lead osteoarthritis RNA treatment, based on a microRNA degradation platform.
  • The treatment is in preclinical development, with clinical trials targeted for the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Future Science & Technology Holdings Co Ltd published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending